ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
Current TAP Partner
Marseille, France, August 29, 2024 – ImCheck Therapeutics announced today that it has received EUR 20.18 million in non-dilutive funding as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government.
The funding will support the development of the company’s most advanced drug candidate, ICT01, a γ9δ2 T cell-activating monoclonal antibody, currently in a Phase I/IIa clinical trial program in various solid cancer and hematologic malignancy indications.
ImCheck has been selected for the French Tech 120 program for the fifth consecutive year, as well as a laureate of the French Tech 2030 program in 2024, recognizing the company as one of the top start-ups/scale-ups contributing to France’s international influence and one of the few organizations developing innovative therapies.